secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0001104659-23-081684
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia enters amended supply agreement with Lonza for YUTREPIA; increased minimum commitments, FDA timeline triggers
--------------------------------------------------------------------------------

- Amended Commercial Manufacturing Services and Supply Agreement with Lonza Tampa for encapsulation/packaging of YUTREPIA (treprostinil) inhalation powder.
- Initial term of 5 years from FDA regulatory approval; Lonza may terminate if FDA does not approve by December 31, 2024.
- Minimum annual order quantities materially increased compared to prior agreement; company may adjust after 13 months post-approval.
- Upon termination for FDA rejection or delay, Liquidia reimburses 50% of Lonza capital equipment costs, cap $2.5 million.
- Company delivers bulk treprostinil powder; Lonza provides encapsulation and storage services as sole supplier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923081684/0001104659-23-081684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923081684/tm2321455d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-081684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer